UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 22, 2018

 

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-188152

 

33-1229553

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3651 Lindell Road, Suite D1141, Las Vegas, NV

 

89103

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (208) 231-1606

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 
 
 
 

 

Item 8.01 Other Items

 

In connection with the change of name of our company as previously announced on our Current Report on Form 8-K filed on December 1, 2017, our company applied to change our ticker symbol from "MJPI" to "BIIO". The change of ticker symbol will be effective on the OTC Markets at the opening of trading on Monday, January 22, 2018.

 

 

2

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BIONOVATE TECHNOLOGIES CORP.

 

/s/ Liao Zu Guo

Liao Zu Guo

Chief Executive Officer

 

Date January 22, 2018

 

 

 

3